What is the weight loss effect after using Zilucoplan?

Zilucoplan is a new drug for the treatment of myasthenia gravis (a rare disease). Its main function is to reduce autoimmune damage by inhibiting C5 activation of the complement system, thereby improving muscle function. However, regarding whether zeleptide causes weight loss, existing research and clinical observations do not show that the drug is directly related to weight loss.

During the use of zeleptide, the weight loss effect is not the intended effect of the drug. The main goal of zeleptide is to reduce the symptoms of muscle weakness and fatigue caused by myasthenia gravis, especially in patients with AChR antibody-positive (AChR-Ab+), and to help patients restore muscle function. The drug reduces damage to muscles and nerves through complement inhibition, thereby slowing the progression of the disease.

Although zeleptide's primary effects are to modulate the immune system, reduce inflammation, and improve a patient's muscle function, in some cases, there may be minor changes in weight due to improved muscle function and increased mobility. Some patients may gain weight during treatment as they regain some ability to exercise, especially in patients who have been inactive for long periods of time due to muscle weakness. However, these weight changes are not a direct effect of the drug and do not constitute the primary effect of drug treatment.

So although zeleptide improves patients' muscle function and helps them regain their ability to perform daily activities, it does not directly lead to weight loss. For weight management, patients still need to achieve it through a combination of reasonable diet and exercise, rather than relying on the therapeutic effect of zeleptide.

Reference materials:https://www.drugs.com/zilucoplan.html